CDC, natural immunity left out
June 21, 2026
13 min
Full
336 of 364

June 21, 2026
CDC, natural immunity left out
0:00 / 13:53
Excerpt playback isn’t available for this episode — use the full-episode link.
Search the Record
Moment search isn’t open for this episode yet
When it opens, you’ll be able to type any phrase and jump straight to the second it was said.
Dr John Campbell Episodes Around June 21, 2026
Episode 336 of 364 — walk the feed in the order it was published.
13:53This episodeCDC, natural immunity left out
Summary
This covid winter should be better than last
Dr. Anthony S. Fauci, President Biden’s chief medical adviser
https://www.nytimes.com/2022/11/22/us/politics/fauci-covid-winter-surge.html
https://www.washingtonpost.com/health/2022/11/22/covid-bivalent-booster/?utm_campaign=wp_to_your_health&utm_medium=email&utm_source=newsletter&wpisrc=nl_tyh
Combination of infections and vaccinations,
enough community protection that we’re not going to see a repeat of what we saw last year at this time
Re bivalent effectiveness
It is clear now, despite an initial bit of confusion
United States
Nearly $5 billion to buy 171 million bivalent boosters
(Pfizer BioNTech, Moderna)
Hobson’s choice
Dr. Ashish K. Jha, White House’s Covid-19 response coordinator
Still heavily promoting vaccination
Nothing I have seen in the subvariants makes me believe that we can’t manage our way through it effectively, especially if people step up and get their vaccine
So far, 35 million people, (11% of over 5s) one bivalent shot
https://www.cdc.gov/mmwr/volumes/71/wr/mm7148e1.htm?s_cid=mm7148e1_w
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022
This is the clinical trial, previous work had only been based on antibodies
Benefits are mentioned, adverse reactions are not
Any adverse reactions not reported
v-safe
https://www.cdc.gov/mmwr/volumes/71/wr/mm7144a3.htm?s_cid=mm7144a3_w
Systemic symptoms
Fatigue (30.0%–53.1%)
Headache (19.7%–42.8%)
Myalgia (20.3%–41.3%)
Fever (10.2%–26.3%)
Reported inability to complete normal daily activities
10.6% among aged over 65 years
19.8% among aged 18–49 years
Bivalent boosters provided significant additional protection against symptomatic SARS-CoV-2 infection
Relative vaccine effectiveness (rVE) of a bivalent booster dose,
compared with that of more than 2 monovalent vaccine doses,
30% and 56% aged 18–49
with relative benefits increasing with time since receipt of the most recent monovalent vaccine dose.
Staying up to date with COVID-19 vaccination, including getting a bivalent booster dose when eligible, is critical to maximizing protection against COVID-19
350,000 tests at almost 10,000 retail pharmacies between Sept. 14 and Nov. 11





























